Open AccessArticle
Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic Parameters
by
1,2,*
, 2,3
, 4
, 2,5, 1,2, 2,5, 6, 2,7, 2,8 and 2,5,6
1
Department of Internal Medicine, Division of Medical Oncology, University of Kentucky, Lexington, KY 40536, USA
2
Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA
3
Department of Neuroscience, University of Kentucky College of Medicine, Lexington, KY 40536, USA
4
Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
5
Department of Urology, University of Kentucky, Lexington, KY 40536, USA
6
Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington KY 40536, USA
7
Department of Internal Medicine-Health Services Research, University of Kentucky, Lexington, KY 40536, USA
8
Department of Radiation Medicine, University of Kentucky, Lexington, KY 40536, USA
*
Author to whom correspondence should be addressed.
Academic Editor: José I. López
Received: 23 March 2021
/
Revised: 24 April 2021
/
Accepted: 28 April 2021
/
Published: 29 April 2021
Simple Summary
High expression levels of glutaminase (GLS1) are reported for several cancers, and correlate with parameters of disease status. GLS1, the rate-limiting enzyme in the glutamine pathway, is involved in DNA/RNA and amino acid synthesis and contributes to other pathways (e.g., TCA cycle). Inhibition of GLS1 has shown anti-tumor activity in both solid tumors and hematological malignancies. The CB-839 agent, a novel GLS1 inhibitor, has been under investigation clinically. GLS1 expression by immunohistochemical (IHC) staining in prostate has not been definitively demonstrated. We present a retrospective study evaluating GLS1 expression utilizing The Cancer Genome Atlas (TCGA) RNA-Seq data and by IHC in formalin-fixed paraffin embedded radical prostatectomy samples. The study showed a significant difference in GLS1 levels between cancer and non-cancer, but fell short as a prognostic marker. As the study cohort was skewed to less aggressive localized prostate cancer, we support further studies that incorporate high-risk and very high-risk localized and metastatic prostate cancers.